TP53 and cancer: Nevertheless, gene therapies, targeted tumor vaccines, and anti-cancer agents for TP53 alteration are still in the early stages of clinical trials, including APR-246, which is a targeted drug for three hot-spot mutations of the TP53 gene (R273, R175, and R248) (52, 53).